2-Bromo-9,9-diphenyl-9H-fluorene | CAS:474918-32-6

We serve 2-Bromo-9,9-diphenyl-9H-fluorene CAS:474918-32-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Bromo-9,9-diphenyl-9H-fluorene

Chemical Name:2-Bromo-9,9-diphenyl-9H-fluorene
CAS.NO:474918-32-6
Synonyms:2-Dibromo-9,9-Diphenylfluorene
2-Bromo-9,9-diphenylfluorene
Molecular Formula:C25H17Br
Molecular Weight:397.30600
 
Physical and Chemical Properties:
Density:1.363
Boiling point:480.5ºC
Flash point:235.7ºC
Index of Refraction:1.681
 
Specification:
Appearance:Off-white powder
Assay:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates



Contact us for information like 2-Bromo-9,9-diphenyl-9H-fluorene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Bromo-9,9-diphenylfluorene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Dibromo-9,9-Diphenylfluorene Use and application,2-Bromo-9,9-diphenyl-9H-fluorene technical grade,usp/ep/jp grade.


Related News: The target screening performed by Retrogenix will focus on hundreds of novel, prioritized antibodies in Resonant’s collection.4-Bromobenzotrifluoride manufacturer Due to the cyclic nature of the upstream chemical products of the API, it is expected that the impact of price fluctuations of raw materials on the performance of API companies is unavoidable, but companies with thick product lines and the ability to produce intermediates are expected to minimize the upstream price impact.2,3,5-三甲基吡嗪 supplier It is frequently associated with the presence of blasts or leukemic cells in the marrow.5-Fluoropicolinic acid vendor Their pharmacological activity plays a direct role in the diagnosis, cure, mitigation, treatment, or prevention of disease.After several years of R & D and improvement, the production process of commonly used generic drug bulk drugs is relatively mature, and the products of similar companies have high similarities. Therefore, the competitive advantage of bulk drug companies is mainly reflected in cost control. Companies with cost advantages can usually pass Competition to expand production capacity and further gain scale advantages, while having stable, high-quality upstream supply.